INTRODUCTIONTropomyosin related kinase B (TrkB) and C (TrkC) receptor signaling promotes synaptic plasticity and interacts with pathways affected by amyloid beta (Aβ) toxicity. Upregulating TrkB/C signaling could reduce Alzheimer's disease (AD)ârelated degenerative signaling, memory loss, and synaptic dysfunction.METHODSPTXâBD10â2 (BD10â2), a small molecule TrkB/C receptor partial agonist, was orally administered to aged London/SwedishâAPP mutant mice (APPL/S) and wildâtype controls. Effects on memory and hippocampal longâterm potentiation (LTP) were assessed using electrophysiology, behavioral studies, immunoblotting, immunofluorescence staining, and RNA sequencing.RESULTSIn APPL/S mice, BD10â2 treatment improved memory and LTP deficits. This was accompanied by normalized phosphorylation of protein kinase B (Akt), calciumâcalmodulinâdependent kinase II (CaMKII), and AMPAâtype glutamate receptors containing the subunit GluA1; enhanced activityâdependent recruitment of synaptic proteins; and increased excitatory synapse number. BD10â2 also had potentially favorable effects on LTPâdependent complement pathway and synaptic gene transcription.DISCUSSIONBD10â2 prevented APPL/S/Aβâassociated memory and LTP deficits, reduced abnormalities in synapseârelated signaling and activityâdependent transcription of synaptic genes, and bolstered transcriptional changes associated with microglial immune response.Highlights
Small molecule modulation of tropomyosin related kinase B (TrkB) and C (TrkC) restores longâterm potentiation (LTP) and behavior in an Alzheimer's disease (AD) model.
Modulation of TrkB and TrkC regulates synaptic activityâdependent transcription.
TrkB and TrkC receptors are candidate targets for translational therapeutics.
Electrophysiology combined with transcriptomics elucidates synaptic restoration.
LTP identifies neuron and microglia ADârelevant humanâmouse coâexpression modules.